REFERENCES
- Barlogie B, Smith L, Alexanian R Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984;310:1353–1356.
- Alexanian R, Barlogie B, Tucker S. VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol 1990;33:86— 89.
- Boccadoro M, Palumbo A, Bringhen S et al. Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma. Haematologica 2002;87:846— 850.
- Tricot G, Jagannath S, Vesole D et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 1995;85:588— 596.
- Barlogie B, Shaughnessy J, Tricot G et al. Treatment of multiple myeloma. Blood 2004;103:20–32.
- Uziely B, Jeffers S, Isacson R et al. Liposomal doxorubicin: antitumor activity and unique toxicities during two comple-mentary phase I studies. J Clin Oncol 1995;13:1777–1785.
- Theodoulou M, Hudis C. Cardiac profiles of liposomal anthracyclines: greater cardiac safety versus conventional doxorubicin? Cancer 2004;100:2052— 2063.
- Blade J, Samson D, Reece D et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102:1115–1123.
- Moloney M, Prince HM, Seymour JF et al. Incidence and predictors of infusion related reactions to liposomal anthracy-clines in patients with haematologic malignancies. Proc Haematol Soc Aust NZ 86.
- Dimopoulos MA, Pouli A, Zervas K et al. Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma. Ann Oncol 2003;14:1039 — 1044.
- Hussein MA, Wood L, Hsi E et al. A phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexa-methasone combination therapy in newly diagnosed multiple myeloma patients. Cancer 2002;95:2160–2168.
- Tsiara SN, Kapsali E, Christou L, Panteli A, Pritsivelis N, Bourantas KL. Administration of a modified chemotherapeu-tic regimen containing vincristine, liposomal doxorubicin and dexamethasone to multiple myeloma patients: preliminary data. Eur J Haematol 2000;65:118–122.